Stock Screener App

Gratuito - Play StoreApp Store

Installare Installare

Dow:

Nasdaq:

S&P 500:

CAPR

$6.979.25%0.59

Capricor Therapeutics Inc (CAPR)

Date: O: H: L: C: Vol:

Capricor Therapeutics Inc Borsa (CAPR) Ultime notizie

Dyno Therapeutics to Present New AAV Capsid Data Across Three Posters at the 33rd Annual Congress of the European Society of Gene & Cell Therapy - Yahoo Finance

Discipline and Rules-Based Execution in CAPR Response - Stock Traders Daily

Stem Cell Therapy Market Set to Experience Steady Growth at a 11.3% CAGR Until 2030 - EIN News

CAPR Stock on Track For Worst Month Since July AdCom Vote On Deramiocel As November FDA Decision Nears - TradingView

Capricor Therapeutics, Inc. Cash Flow – XETR:4LN2 - TradingView

We're Keeping An Eye On Capricor Therapeutics' (NASDAQ:CAPR) Cash Burn Rate - Moomoo

Capricor Therapeutics, Inc. (CAPR) options chain - Yahoo Finance Australia

Why did CAPR, LKQ, PSKY Stocks Plunge To 52-Week Lows Today? - Stocktwits

Millennium Management Trims Capricor Therapeutics (CAPR) Stake b - GuruFocus

Voting power over 1.67M Capricor (CAPR) shares is shared by three reporting parties. - Stock Titan

Capricor Faces Make-Or-Break FDA Panel For Duchenne Cell Therapy — Experts And Investors Weigh In - Stocktwits

Capricor Therapeutics, Inc. (CAPR) Discusses HOPE-3 Open-Label Extension Data and Deramiocel Update for Duchenne Muscular Dystrophy - Slideshow (NASDAQ:CAPR) 2026-10-13 - Seeking Alpha

Analysts Expect Breakeven For Capricor Therapeutics, Inc. (NASDAQ:CAPR) Before Long - Simply Wall Street

Capricor reports 24-month data for Duchenne therapy deramiocel By Investing.com - Investing.com South Africa

What's Going On With Capricor Therapeutics Stock Monday? - Benzinga

Capricor Therapeutics (CAPR) Shares Drop 10% Despite Positive Du - GuruFocus

H.C. Wainwright Sees Mixed Signals in Capricor Therapeutics (CAP - GuruFocus

Capricor drops as deramiocel OLE data fails to quell regulatory concerns - Seeking Alpha

Capricor’s DMD Therapy Shows 76% Slower Upper-Limb Decline — This Analyst Expects A Complete Response Letter In November - Yahoo Finance

Roth Capital Maintains Neutral on Capricor Therapeutics (CAPR) A - GuruFocus

Capricor Therapeutics (CAPR) Reports Positive HOPE-3 Study Data on Deramiocel for Duchenne Muscular Dystrophy - GuruFocus

Capricor reports 24-month data for Duchenne therapy deramiocel - Investing.com

Capricor Therapeutics Reports Positive 24-Month HOPE-3 Data for Deramiocel in Duchenne Muscular Dystrophy - Quiver Quantitative

Capricor Therapeutics Presents Positive HOPE-3 Open-Label Extension Data on Upper Limb Function in Duchenne Muscular Dystrophy at 2026 World Muscle Society Congress - Yahoo Finance

After a year on placebo, patients’ arm-function decline rate was 76% lower on treatment - Stock Titan

Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada

Capricor Therapeutics, Inc. (CAPR) - Yahoo! Finance Canada

Small-Cap Biotech Capricor Therapeutics (CAPR) Sees Elevated Sho - gurufocus.com

Capricor Therapeutics Shares Jump as Two-Year Data Bolster Duchenne Drug Case - finance.biggo.com

CAPR Stock Jumps As Analysts Hike Price Targets Into FDA Date - StocksToTrade

Capricor Therapeutics Stock Surges: What's Going On? - Benzinga

CAPR Stock Pops As Analysts Hike Targets Ahead FDA Call - timothysykes.com

CAPR Stock Jumps As Analysts Hike Price Targets Ahead FDA Call - StocksToTrade

CAPR Stock Jumps As Analysts Hike Targets Ahead Of FDA Date - timothysykes.com

CAPR Stock Jumps As Street Hikes Price Targets Into FDA Catalyst - StocksToTrade

Capricor Therapeutics, Inc. stock Analysis: Bearish Trend and Intraday Pause - The Cryptonomist

Capricor Therapeutics (CAPR) Shares Surge on Positive Phase 3 Da - gurufocus.com

Capricor jumps as study shows longer-term effects of deramiocel (CAPR:NASDAQ) - Seeking Alpha

Total equity of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView

Return on equity % of Capricor Therapeutics, Inc. – HAN:4LN2 - TradingView

Recover Investment Losses: Class Action Initiated Against Capricor Therapeutics, Inc. (CAPR) - ACCESS Newswire

CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - 巴士的報

CAPR CLASS ACTION DEADLINE TONIGHT: Faruqi & Faruqi, LLP Reminds Capricor Investors of Securities Class Action Lawsuit Deadline on September 28, 2026 - Bluefield Daily Telegraph

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff - globenewswire.com

CAPR Investors Have Opportunity to Lead Capricor Therapeutics, Inc. Securities Fraud Lawsuit with SBS Law - Business Wire

CAPR Alert: Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors Urged to Contact Hagens Berman; Securities Fraud Class Action Filed, September 28, 2026 Lead Plaintiff Deadline - PR Newswire

CAPR 3-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - PR Newswire

CAPR INVESTOR DEADLINE: Rosen Law Firm Reminds Capricor Therapeutics, Inc. Investors of September 28 Lead Plaintiff Deadline in Securities Class Action - TMX Newsfile

CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. - GlobeNewswire

CAPR 2-DAY DEADLINE ALERT: Capricor Therapeutics, Inc. Investors with Substantial Losses Have Opportunity to Lead Shareholder Class Action Lawsuit Before September 28, 2026 Deadline - GlobeNewswire Inc.

Simile a CAPR

ZVRA$10.072.04%